Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients
Daisuke Kanai, Hiromichi Wakui, Tatsuya Haze, Kengo Azushima, Sho Kinguchi, Tomohiko Kanaoka, Yoshiyuki Toya, Nobuhito Hirawa, Hideaki Kato, Kazushi Uneda, Fumimasa Watanabe, Kanako Hanaoka, Masaaki Hanaoka, Hiroshi Mitsuhashi, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura
Abstract
A third dose of SARS-CoV-2 mRNA vaccine has been administered in several countries.1,2 Patients with end-stage kidney disease have a weak immune response to 2-sessional doses of the mRNA vaccine.3–7 Because patients undergoing hemodialysis (HD) are at a high risk for COVID-19 severity and death, they have been prioritized in vaccination programs worldwide.8,9
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Immune systemHemodialysisVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmunologyDiseaseIntensive care medicineInternal medicineVirologyInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 Impact on Reproduction